| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | IgG immunoglobulin complex | 2.51e-06 | 14 | 41 | 3 | GO:0071735 | |
| GeneOntologyCellularComponent | IgD immunoglobulin complex | 5.60e-05 | 6 | 41 | 2 | GO:0071738 | |
| GeneOntologyCellularComponent | IgE immunoglobulin complex | 5.60e-05 | 6 | 41 | 2 | GO:0071742 | |
| GeneOntologyCellularComponent | IgA immunoglobulin complex | 3.88e-04 | 15 | 41 | 2 | GO:0071745 | |
| GeneOntologyCellularComponent | IgM immunoglobulin complex | 3.88e-04 | 15 | 41 | 2 | GO:0071753 | |
| GeneOntologyCellularComponent | cytoplasmic region | 6.63e-04 | 360 | 41 | 5 | GO:0099568 | |
| Domain | AT_hook | 1.44e-03 | 27 | 39 | 2 | SM00384 | |
| Domain | AT_hook_DNA-bd_motif | 1.44e-03 | 27 | 39 | 2 | IPR017956 | |
| Domain | C1_1 | 6.31e-03 | 57 | 39 | 2 | PF00130 | |
| Domain | ZF_DAG_PE_1 | 7.89e-03 | 64 | 39 | 2 | PS00479 | |
| Domain | ZF_DAG_PE_2 | 7.89e-03 | 64 | 39 | 2 | PS50081 | |
| Domain | C1 | 8.13e-03 | 65 | 39 | 2 | SM00109 | |
| Domain | PE/DAG-bd | 8.38e-03 | 66 | 39 | 2 | IPR002219 | |
| Domain | LIM | 9.13e-03 | 69 | 39 | 2 | PF00412 | |
| Domain | - | 9.38e-03 | 70 | 39 | 2 | 2.10.110.10 | |
| Domain | LIM_DOMAIN_2 | 9.64e-03 | 71 | 39 | 2 | PS50023 | |
| Domain | Znf_LIM | 9.64e-03 | 71 | 39 | 2 | IPR001781 | |
| Domain | LIM_DOMAIN_1 | 9.64e-03 | 71 | 39 | 2 | PS00478 | |
| Domain | LIM | 9.64e-03 | 71 | 39 | 2 | SM00132 | |
| Pubmed | TWIST1 and chromatin regulatory proteins interact to guide neural crest cell differentiation. | 9.32e-06 | 109 | 42 | 4 | 33554859 | |
| Pubmed | 1.14e-05 | 36 | 42 | 3 | 33737325 | ||
| Pubmed | The arrestin domain-containing 3 protein regulates body mass and energy expenditure. | 1.42e-05 | 5 | 42 | 2 | 21982743 | |
| Pubmed | The cytoplasmic tail of fibrocystin contains a ciliary targeting sequence. | 1.42e-05 | 5 | 42 | 2 | 20048263 | |
| Pubmed | Arf4 is required for Mammalian development but dispensable for ciliary assembly. | 2.98e-05 | 7 | 42 | 2 | 24586199 | |
| Pubmed | Structure and expression of the human immunoglobulin lambda genes. | 5.10e-05 | 9 | 42 | 2 | 2115572 | |
| Pubmed | 6.18e-05 | 63 | 42 | 3 | 15475267 | ||
| Pubmed | 1.48e-04 | 15 | 42 | 2 | 23236378 | ||
| Pubmed | 1.48e-04 | 15 | 42 | 2 | 20176268 | ||
| Pubmed | Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. | 1.91e-04 | 17 | 42 | 2 | 17554260 | |
| Pubmed | 2.40e-04 | 19 | 42 | 2 | 23563609 | ||
| Pubmed | Loss of Zeb2 in mesenchyme-derived nephrons causes primary glomerulocystic disease. | 2.95e-04 | 21 | 42 | 2 | 27591083 | |
| Pubmed | 3.54e-04 | 23 | 42 | 2 | 20468071 | ||
| Pubmed | 3.77e-04 | 116 | 42 | 3 | 21282530 | ||
| Pubmed | Hand2 is an essential regulator for two Notch-dependent functions within the embryonic endocardium. | 3.86e-04 | 24 | 42 | 2 | 25497097 | |
| Pubmed | 5.09e-04 | 847 | 42 | 6 | 35850772 | ||
| Pubmed | Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. | 7.34e-04 | 33 | 42 | 2 | 20203524 | |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | 8.37e-04 | 1294 | 42 | 7 | 30804502 | |
| Pubmed | 9.44e-04 | 159 | 42 | 3 | 22751105 | ||
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | 9.47e-04 | 954 | 42 | 6 | 36373674 | |
| Pubmed | Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. | 9.79e-04 | 161 | 42 | 3 | 32572027 | |
| Cytoband | 14q31.3 | 6.33e-05 | 13 | 42 | 2 | 14q31.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr22q11 | 5.82e-04 | 419 | 42 | 4 | chr22q11 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr14q31 | 1.35e-03 | 59 | 42 | 2 | chr14q31 | |
| GeneFamily | LIM domain containing | 3.75e-03 | 59 | 28 | 2 | 1218 | |
| GeneFamily | WD repeat domain containing | 7.54e-03 | 262 | 28 | 3 | 362 | |
| GeneFamily | Immunoglobulin lambda locus at 22q11.2 | 8.33e-03 | 89 | 28 | 2 | 353 | |
| GeneFamily | PDZ domain containing | 2.30e-02 | 152 | 28 | 2 | 1220 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 2.37e-02 | 718 | 28 | 4 | 28 | |
| ToppCell | TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-6|TCGA-Liver / Sample_Type by Project: Shred V9 | 1.92e-05 | 169 | 42 | 4 | e992530776cab922d0360b275fb9cb8bd0017b06 | |
| ToppCell | Healthy-Plasmablast|Healthy / disease group, cell group and cell class | 2.31e-05 | 177 | 42 | 4 | 4ff75c609ac9edf7a94bda42eb7124c559e8b6aa | |
| ToppCell | Control-Epithelial_alveolar-AT_1-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.31e-05 | 177 | 42 | 4 | 9af14a056eb6d88c6f11b09f6d4c0d3448d647d5 | |
| ToppCell | LV|World / Chamber and Cluster_Paper | 2.46e-05 | 180 | 42 | 4 | 5ac6f485a58bb29462fec02dfbe8eb70864eafe3 | |
| ToppCell | RV|World / Chamber and Cluster_Paper | 2.52e-05 | 181 | 42 | 4 | bbe1e6e59d8889bd37d6e8303116cbdcafca7236 | |
| ToppCell | PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.57e-05 | 182 | 42 | 4 | 573771130247e869e4e58f22d4a1cb31989635cf | |
| ToppCell | PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.57e-05 | 182 | 42 | 4 | 6cfaa2b3b3974c13b01c943f4adb70768dcc35e4 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.68e-05 | 184 | 42 | 4 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.68e-05 | 184 | 42 | 4 | bd786db4dc4edae6d5cfc0b69901983dea19f729 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.68e-05 | 184 | 42 | 4 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.68e-05 | 184 | 42 | 4 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | LV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper | 2.74e-05 | 185 | 42 | 4 | 6baccb26f999145e51b91d94315bf8d4655bef31 | |
| ToppCell | Control-Endothelial-Endothelial-Vein|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.80e-05 | 186 | 42 | 4 | 92092f11ecce22c14f244e42c499af0822977e6f | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.86e-05 | 187 | 42 | 4 | f124d2c699b717b7c02a1a70493f515b83dc2f4c | |
| ToppCell | LV-04._Ventricular_Cardiomyocyte_I|World / Chamber and Cluster_Paper | 2.92e-05 | 188 | 42 | 4 | 0758b474457efa36488e0195f7357100f4b6a090 | |
| ToppCell | RV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 2.98e-05 | 189 | 42 | 4 | 5e80c47f63980904c4c1ff02c201b67b456a0974 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.98e-05 | 189 | 42 | 4 | e32172ad09e93f6ac6ea2b92145b2b73003f7970 | |
| ToppCell | LV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 3.04e-05 | 190 | 42 | 4 | de5ef606a002f85c2e0e3a36c1f259d0b85a76ff | |
| ToppCell | LV-06._Ventricular_Cardiomyocyte_II|LV / Chamber and Cluster_Paper | 3.10e-05 | 191 | 42 | 4 | 25f3eb34f4e70761e81e84c8a5829f216108cbc6 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.10e-05 | 191 | 42 | 4 | d9a6f61fcda4f5352488f7f55cb9b57aeacc717f | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|World / Lineage, Cell type, age group and donor | 3.10e-05 | 191 | 42 | 4 | d3733c8c4bda70c4390e5601fdda6188a64be944 | |
| ToppCell | LV-04._Ventricular_Cardiomyocyte_I|LV / Chamber and Cluster_Paper | 3.17e-05 | 192 | 42 | 4 | ad19e2c1d36a0566c9b12ced10db78f4781c8ea6 | |
| ToppCell | Healthy_donor-CD8+_Tem|Healthy_donor / disease group, cell group and cell class (v2) | 3.30e-05 | 194 | 42 | 4 | bf2e889de60b2b452a41f4d59a0f2a1865f07184 | |
| ToppCell | Healthy/Control-CD8+_Tem|Healthy/Control / Disease group and Cell class | 3.37e-05 | 195 | 42 | 4 | f4955c176c4918052dc151c5e5249223ec428272 | |
| ToppCell | Healthy_donor-CD8+_Tem|World / disease group, cell group and cell class (v2) | 3.43e-05 | 196 | 42 | 4 | b04684d319d0c462862677d0f956a389bffef535 | |
| ToppCell | severe_COVID-19-CD4+_CTL|severe_COVID-19 / disease group, cell group and cell class (v2) | 3.50e-05 | 197 | 42 | 4 | e51b7cd03b1450dc8601b4be0453b104d6a5f955 | |
| ToppCell | severe_influenza-CD8+_Tem|severe_influenza / disease group, cell group and cell class (v2) | 3.57e-05 | 198 | 42 | 4 | 19d9516a04b75e2c8b6b66b5af25b319b0641ac9 | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT1|Control_saline / Treatment groups by lineage, cell group, cell type | 3.57e-05 | 198 | 42 | 4 | 85f424cd9bb3117c9e322031024aabb87696ce47 | |
| ToppCell | Sepsis-Int-URO-Lymphocyte-T/NK-CD4+_CTL|Int-URO / Disease, condition lineage and cell class | 3.57e-05 | 198 | 42 | 4 | 717735d755745439f97ba1b71785c73945dfa9c5 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.64e-05 | 199 | 42 | 4 | d43c605a4ff221cf78d91678c15d2ad20f831c7f | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.64e-05 | 199 | 42 | 4 | 121de4e02585de3a3010398387c523bacf8ce546 | |
| ToppCell | severe-gd_T|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.64e-05 | 199 | 42 | 4 | e5a17a9f8f3be05d6abe1116607d17633df3c7ef | |
| ToppCell | mild-CD8+_Tem|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.72e-05 | 200 | 42 | 4 | d8aec4904c9420b8f9d7508658ba1e36c66cdfcc | |
| ToppCell | severe-CD8+_Tem|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.72e-05 | 200 | 42 | 4 | aaa2cd326dc15dee2fd975ca133359c5826f6a75 | |
| ToppCell | Thalamus|World / BrainAtlas - Mouse McCarroll V32 | 1.78e-04 | 116 | 42 | 3 | 5ddfb2dd5459ff6d7ae38163a38eae64fda283b7 | |
| ToppCell | COVID-19-kidney-Epithelial_Doublet|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.49e-04 | 130 | 42 | 3 | 1ff28e9d3dc9a791e07d815f8fbb48f75d3f275b | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 4.02e-04 | 153 | 42 | 3 | 764fb5e5fa028c137b8ea65dcd5e4ec9b22191e9 | |
| ToppCell | T_cells-GNLY+GZMB+_T_cells|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 4.33e-04 | 157 | 42 | 3 | e9eb56a1dd96bd2e9725a20f2cf70ddeab811bd6 | |
| ToppCell | 367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.41e-04 | 158 | 42 | 3 | c08b5e12cc2975e52965e22ec987d0d45a9a68e9 | |
| ToppCell | FLU-Healthy-1|Healthy / Virus stimulation, Condition and Cluster | 4.49e-04 | 159 | 42 | 3 | 97c8e16a7ac10ebba96daee97f9fb1d4a404f23b | |
| ToppCell | FLU-Healthy-1|FLU / Virus stimulation, Condition and Cluster | 4.49e-04 | 159 | 42 | 3 | fe2a9f79b058e89214256e736f6e266830cdfa28 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 160 | 42 | 3 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 160 | 42 | 3 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_B1|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.66e-04 | 161 | 42 | 3 | f470b662566131dfe69a2fd01186ac8491196396 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.66e-04 | 161 | 42 | 3 | 5fba13f0aa5002f7eefe219e2c6a07e163f1a50d | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.75e-04 | 162 | 42 | 3 | 80317c4253bf8e897782e562f29835f181c65b98 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 4.83e-04 | 163 | 42 | 3 | 8f24cef152f5965727bbeee116bd26c75cbba82a | |
| ToppCell | Control|World / group, cell type (main and fine annotations) | 5.27e-04 | 168 | 42 | 3 | a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 5.27e-04 | 168 | 42 | 3 | b94b1f37c92e019d01ecfa3b7cc6797b6e4a56ff | |
| ToppCell | PND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.27e-04 | 168 | 42 | 3 | a7eb28e15b591997f1aee09501cb20ae18beca08 | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Stem-like-OPC-like-OPC-like_Prolif-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.37e-04 | 169 | 42 | 3 | 2833a8a7094e4d407eb923f2bc59b9b112c6bae4 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.37e-04 | 169 | 42 | 3 | 12bdc709bc000d7f9061ecd9fbd57233eaacb7e2 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-NK-NK-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.46e-04 | 170 | 42 | 3 | aaf29c2d4de172d366cbfc863bc741941667dde1 | |
| ToppCell | PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-Developping_Plasmablast|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.55e-04 | 171 | 42 | 3 | 13126a3fbee181412c13ffb0c347277b9d8f16f7 | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 5.55e-04 | 171 | 42 | 3 | 6be81c20f4e962b414afcedfe478dd59c510d1e1 | |
| ToppCell | E12.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.65e-04 | 172 | 42 | 3 | 3b9be685fcd1634498a603b692f5ac6ddd0de176 | |
| ToppCell | E12.5-Endothelial-proliferative_endothelial_cell-proliferative_endothelial_cell|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.65e-04 | 172 | 42 | 3 | ba99688e9f46671deccf824b1e77c6db0742d7df | |
| ToppCell | E12.5-Endothelial-proliferative_endothelial_cell|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.65e-04 | 172 | 42 | 3 | 2136170f6e1204734cec7dbf7b32e7d5179b92b5 | |
| ToppCell | 15-Trachea-Immune-Hematopoietic,_Natural_Killer_Cell|Trachea / Age, Tissue, Lineage and Cell class | 5.74e-04 | 173 | 42 | 3 | 6884af1492e8a3bb92a33303d4d5ec3343e88b00 | |
| ToppCell | 5'-Adult-Appendix-Hematopoietic-Myeloid-Mast_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.74e-04 | 173 | 42 | 3 | a7dee23b1d43d3070d502487af319ff81a9a747b | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 5.74e-04 | 173 | 42 | 3 | 1e8a43ff32eab95857c794e0bf4f0b0dba155b4a | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_T-T_NK-CD8_T_cell|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.84e-04 | 174 | 42 | 3 | fee2ee3e888ce71f9f3f05d7dc8aaa9549480205 | |
| ToppCell | severe_influenza-Plasmablast|World / disease group, cell group and cell class (v2) | 5.94e-04 | 175 | 42 | 3 | e6d6c44510d5dc4eb0bae820125e42366f7a4e74 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.94e-04 | 175 | 42 | 3 | 316f2ea930437bf1243b1c0f45e6bd864112c6f2 | |
| ToppCell | 10x5'-blood-Lymphocytic_B_plasma-Plasmablasts|blood / Manually curated celltypes from each tissue | 5.94e-04 | 175 | 42 | 3 | 2e048bf7961c3d86b6e12a1ebae3b3f2359af457 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.94e-04 | 175 | 42 | 3 | a9f08e1e4c2997dcdd3e5d92daac480da19100b8 | |
| ToppCell | Influenza_Severe-Plasmablast|World / Disease group and Cell class | 5.94e-04 | 175 | 42 | 3 | 14df8fc6f6beae1be7b7bd5837546d1ac1239a6f | |
| ToppCell | Control-Lymphocyte-T_NK-CD8_TCM|Control / Disease, Lineage and Cell Type | 6.04e-04 | 176 | 42 | 3 | 1a7948eb86ee1da607db4d0576312b2859d94523 | |
| ToppCell | COVID-19-kidney-Distal_Epi_Doublet_(PCT)|kidney / Disease (COVID-19 only), tissue and cell type | 6.04e-04 | 176 | 42 | 3 | 36f77d878a53b30465b0dea8333a3865dba75613 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L3-5_THEMIS_ELOF1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.04e-04 | 176 | 42 | 3 | 78306517b1e52411a2ba72f141efea4d12c09f25 | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_T-T_NK-NK_T_cell|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.14e-04 | 177 | 42 | 3 | e1ba7e17af2c54d3c78cdf85882168c5b896e453 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L3_LINC00507_CTXN3|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.14e-04 | 177 | 42 | 3 | 96d639407f79669f3990138793d157b94273581c | |
| ToppCell | Control-Epithelial_alveolar-AT_1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.24e-04 | 178 | 42 | 3 | aa7d43c655df493f1330a5001efaa484e4a19f69 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|390C / Donor, Lineage, Cell class and subclass (all cells) | 6.24e-04 | 178 | 42 | 3 | 375c9449be570b4aed83611f9c6fe1665e677818 | |
| ToppCell | normal-na-Lymphocytic_B-plasmablast-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 6.24e-04 | 178 | 42 | 3 | 40a280c1e35963dd45d1809a3e85b568344dd1f5 | |
| ToppCell | normal-na-Lymphocytic_B-plasmablast|normal / PBMC cell types (v2) per disease, treatment status, and sex | 6.24e-04 | 178 | 42 | 3 | 4fe87c713770173336177e3488f7b4a3be54f71b | |
| ToppCell | COVID-19-kidney-Epi_(Mes)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.24e-04 | 178 | 42 | 3 | 544379f5a6145429762258d426b876bb36c112f5 | |
| ToppCell | normal-na-Lymphocytic_T-CD4-positive,_alpha-beta_T_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 6.24e-04 | 178 | 42 | 3 | fa3585383a1e7da460c88a802aaa81246d681b6b | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.34e-04 | 179 | 42 | 3 | 5be883d7d0be3180bb9844e4a757f0dd247294e4 | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-gdT|Multiple_Sclerosis / Disease, Lineage and Cell Type | 6.34e-04 | 179 | 42 | 3 | ab8d8104b38603ec7fbc5b35d7149e71ad57c43a | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.34e-04 | 179 | 42 | 3 | 04ce3673e46606f63d9c87bcba3a64c96817d812 | |
| ToppCell | BLOOD--(5)_Plasma| / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 6.45e-04 | 180 | 42 | 3 | 1ac0a0a715f4a36df0762bb0de44802d6ffa284c | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.45e-04 | 180 | 42 | 3 | 557453b74d4a9cc95ed1c7b9a9a58e45eb02ed6a | |
| ToppCell | BLOOD--(5)_Plasmablasts| / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 6.45e-04 | 180 | 42 | 3 | 4b9be1b19d4ecd0a3b924e4557a1ecfbcff2d705 | |
| ToppCell | COVID-19-kidney-PCT-S2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.45e-04 | 180 | 42 | 3 | 358923e4228035a3e90e2957392089219e90dcd7 | |
| ToppCell | COVID-19-kidney-tDL|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.45e-04 | 180 | 42 | 3 | 864c895b5eaedefae86f5829fa344f7b686fb59f | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 6.55e-04 | 181 | 42 | 3 | 25915e2500430a902db37d79a749ce2990b69810 | |
| ToppCell | MS|World / Condition, Cell_class and T cell subcluster | 6.55e-04 | 181 | 42 | 3 | 99f054a586a95947528dc3fd8043c1bda5e74cc4 | |
| ToppCell | normal_Lymph_Node-B_lymphocytes-Plasma_cells|normal_Lymph_Node / Location, Cell class and cell subclass | 6.55e-04 | 181 | 42 | 3 | 949ac3b60e7fb5968da4c4e872965fb4e10f4a35 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.55e-04 | 181 | 42 | 3 | b45b11428d13950369347e051d4d517efb2bd4fd | |
| ToppCell | T_cells-Resident_memory_CD8+_T_cells|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis | 6.66e-04 | 182 | 42 | 3 | 111d434b89902ec11fb07f41b8ee1a98f3991b61 | |
| ToppCell | COVID-19-kidney-Distal_Epi_Doublet_(PCT)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.66e-04 | 182 | 42 | 3 | 9d67717a6e13bcb54c1297a3e4e3abf4e51628a3 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Endothelial-blood_vessel_EC-Mature_venous_EC|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.76e-04 | 183 | 42 | 3 | 52af3c943116073c8ddd207b664342960b88929b | |
| ToppCell | COVID-19-kidney-PCT-S1|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.76e-04 | 183 | 42 | 3 | 6878d14026c3df6aa12e45dfad94b32fa9d9b0b7 | |
| ToppCell | COPD-Epithelial-ATII|World / Disease state, Lineage and Cell class | 6.76e-04 | 183 | 42 | 3 | 8e9aab4eeec2e282c2cab9bfca6dbf40d660c7b9 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.76e-04 | 183 | 42 | 3 | 42dc31d587fbb9724b2f0be5ee8ed77233f67b86 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.87e-04 | 184 | 42 | 3 | 42ce855b4f8475a8298192feec785bdc69bc5bb0 | |
| ToppCell | COVID-19-Epithelial_cells-AT2|COVID-19 / group, cell type (main and fine annotations) | 6.87e-04 | 184 | 42 | 3 | 369b82f793deab672204558ae4e112cfa5aa9ccc | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.87e-04 | 184 | 42 | 3 | 6b2449ac65a2322aa0479fba0d89828f243aabbe | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.87e-04 | 184 | 42 | 3 | e90622b82fa7f16a1faaf7a4724c958f2d83341d | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 2.69e-04 | 49 | 28 | 3 | GAVISH_3CA_MALIGNANT_METAPROGRAM_36_IG | |
| Disease | Ciliopathies | 1.51e-05 | 110 | 40 | 4 | C4277690 | |
| Disease | disease of metabolism (is_implicated_in) | 2.68e-05 | 6 | 40 | 2 | DOID:0014667 (is_implicated_in) | |
| Disease | tetralogy of Fallot (implicated_via_orthology) | 1.61e-04 | 14 | 40 | 2 | DOID:6419 (implicated_via_orthology) | |
| Disease | matrix metalloproteinase 1 measurement | 1.86e-04 | 15 | 40 | 2 | EFO_0010588 | |
| Disease | Proteinuria | 1.86e-04 | 15 | 40 | 2 | HP_0000093 | |
| Disease | Drug habituation | 5.13e-04 | 115 | 40 | 3 | C0013170 | |
| Disease | Substance-Related Disorders | 5.13e-04 | 115 | 40 | 3 | C0236969 | |
| Disease | Drug abuse | 5.13e-04 | 115 | 40 | 3 | C0013146 | |
| Disease | Drug Use Disorders | 5.13e-04 | 115 | 40 | 3 | C0013222 | |
| Disease | Drug Dependence | 5.13e-04 | 115 | 40 | 3 | C1510472 | |
| Disease | Substance Dependence | 5.13e-04 | 115 | 40 | 3 | C0038580 | |
| Disease | Substance Use Disorders | 5.13e-04 | 115 | 40 | 3 | C0038586 | |
| Disease | Organic Mental Disorders, Substance-Induced | 5.13e-04 | 115 | 40 | 3 | C0029231 | |
| Disease | Prescription Drug Abuse | 5.13e-04 | 115 | 40 | 3 | C4316881 | |
| Disease | Substance abuse problem | 5.26e-04 | 116 | 40 | 3 | C0740858 | |
| Disease | stroke | 9.85e-04 | 144 | 40 | 3 | EFO_0000712 | |
| Disease | myocardial infarction | 1.27e-03 | 350 | 40 | 4 | EFO_0000612 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TSPFKYQSLLTKNKA | 136 | P07550 | |
| SNYTPQKVKQQTAVS | 1146 | Q5TGY3 | |
| QPNVASATKKFSYKL | 146 | Q8N5I2 | |
| NNNYKQSFKKVTPSS | 706 | Q9UFE4 | |
| YFTFIKDQTVTNPKT | 2371 | Q6ZS30 | |
| QPQPKSYFKSISVTK | 201 | O00165 | |
| RYVKAFPFTNKNQQK | 261 | Q9Y5Y7 | |
| SASPVYQAVIKSQNK | 241 | O75112 | |
| PSKKKKFQTNYASTT | 3836 | Q2LD37 | |
| KTSTPFNKSNKAASQ | 4381 | Q2LD37 | |
| IQPTTNKQSFSYTKI | 456 | Q8WW38 | |
| NKQSFSYTKIKSEPS | 461 | Q8WW38 | |
| FTKNYKPVVQTTGNA | 296 | Q6PIU2 | |
| KSKQTTNFENPIYAQ | 4586 | P98164 | |
| FQYPSQQATVKKSSK | 211 | Q9UGU5 | |
| TKPSKQSNNKYAASS | 56 | P0CG04 | |
| VETTKPSKQSNNKYA | 161 | B9A064 | |
| NFVVVFKNNSTKKQY | 986 | Q9BYX4 | |
| FSNAKAYTPNKRSKI | 1386 | Q9NSI6 | |
| FTESQKTKYPTQSGK | 801 | Q9GZR7 | |
| TKPSKQSNNKYAASS | 56 | A0M8Q6 | |
| KQATKYPAAQATSTA | 1006 | D6RIA3 | |
| QLFNAKNSSYSPQKK | 426 | Q6P995 | |
| YSQPKNSQDVLKTFK | 541 | Q9UPQ0 | |
| KNTVTFSKFNFSKSN | 201 | O15547 | |
| SKNFSYNLQSATQPK | 1046 | Q9Y283 | |
| DTYTKLFQVKPANQK | 366 | A2RUB1 | |
| QTNSIRNYFQPSTKK | 451 | O60934 | |
| RKKFSVQSPTKNHYT | 326 | Q8IZU2 | |
| AVVYVFSAPQNSVKK | 3181 | P08F94 | |
| RSKPKTDSYNQTKNS | 206 | Q8IYA6 | |
| NNPKVKFSSQQAATK | 86 | O75475 | |
| KTFSQPSYLSQHKKI | 311 | Q9P2J8 | |
| LKVKFTNSNTPNSYN | 536 | Q5JTV8 | |
| TAGQTKSPKFSYTFK | 46 | Q8NB66 | |
| KQQKYPTKVSFSSQE | 1381 | Q8NI35 | |
| YKNNSKSLFNTLQKP | 111 | Q9P0W8 | |
| VTPVQASSDSFYNKK | 751 | Q8N9V7 | |
| SYPSLQQKTNAVKKL | 126 | Q8NB50 | |
| SNINQKVKFQPLSKY | 346 | O95363 | |
| VTKTTNYSTVPQKQT | 366 | Q6PJT7 | |
| SSTDDKKFTVKYPQN | 116 | Q8IZ20 | |
| ATQNPKTSFSYEKLQ | 1386 | Q9BYP7 | |
| QTSTKQKTNKPTYNE | 56 | P24723 | |
| KFSKTVQGKVQSSYL | 936 | Q14CX7 |